|
Astrocytoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Material and methods We examined 17 oligodendrogliomas (O II, 11 with LOH1p), 16 oligoastrocytomas (OA II, 5 with LOH1p) and 7 astrocytomas (A II, none with LOH1p).
|
18726700 |
2008 |
|
Giardiasis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We detected Encephalitozoon cuniculi genotypes I and II (7.5%), Enterocytozoon bieneusi genotype D and three novel genotypes (gorilla 1-3) (4.0%), Giardia intestinalis subgroup A II (2.0%) and Cryptosporidium bovis (0.5%) in gorillas, whereas in humans we found only G. intestinalis subgroup A II (2.1%).
|
23951255 |
2013 |
|
Sarcoidosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our results showed a strong correlation between the uncommon TNF A II allele and sarcoidosis-associated erythema nodosum.
|
11411907 |
2001 |
|
Tremor
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
Atypical porcine pestivirus (APPV) has been considered a novel pestivirus and causative agent of congenital tremor type A-II.
|
28710801 |
2018 |
|
Tremor
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
This novel porcine pestivirus was first described in 2015 in the USA, where it has been associated with congenital tremor type A-II in new-born piglets.
|
31835549 |
2019 |
|
Tularemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Tularemia is caused by two subspecies of Francisella tularensis, F. tularensis subsp. tularensis (type A) and F. tularensis subsp. holarctica (type B).F. tularensis subsp. tularensis is further subdivided into two genetically distinct populations (A.I and A.II) that differ with respect to geographical location, anatomical source of recovered isolates, and disease outcome.
|
18024683 |
2008 |
|
Tularemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Phylogenetic Analysis of Francisella tularensis Group A.II Isolates from 5 Patients with Tularemia, Arizona, USA, 2015-2017.
|
31002053 |
2019 |
|
Erythema Nodosum
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our results showed a strong correlation between the uncommon TNF A II allele and sarcoidosis-associated erythema nodosum.
|
11411907 |
2001 |
|
Marfan Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
SSCP band alteration was detected in the PCR products for exon 25 in MFS(A) II:1.
|
12890380 |
2003 |
|
Adult Anaplastic Astrocytoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The WHO 2007 classification of tumors of the CNS distinguishes between diffuse astrocytoma WHO grade II (A II(WHO2007)) and anaplastic astrocytoma WHO grade III (AA III(WHO2007)).
|
25962792 |
2015 |
|
Anaplastic astrocytoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The WHO 2007 classification of tumors of the CNS distinguishes between diffuse astrocytoma WHO grade II (A II(WHO2007)) and anaplastic astrocytoma WHO grade III (AA III(WHO2007)).
|
25962792 |
2015 |
|
Cholesteryl Ester Transfer Protein Deficiency
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sequence analysis of proteins or DNA from patients with HDL deficiency or hyperalphalipoproteinemia as well as from randomly screened probands has helped to identify a series of molecular defects in the genes of apolipoprotein (apo) A-I, apo A-II, apo A-IV, apo C-III, lecithin cholesterol acyltransferase, and cholesterol ester-transfer protein.
|
8462178 |
1993 |
|
Grade III Childhood Astrocytoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The WHO 2007 classification of tumors of the CNS distinguishes between diffuse astrocytoma WHO grade II (A II(WHO2007)) and anaplastic astrocytoma WHO grade III (AA III(WHO2007)).
|
25962792 |
2015 |
|
Arteriosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Nevertheless, some effects of apo A-II on intermediate HDL metabolism might improve reverse cholesterol transport and might reduce atherosclerosis development while some other effects might be deleterious.
|
12119188 |
2002 |
|
Arteriosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Because LpA-I has been proposed to be more protective than LpA-I:A-II against atherosclerosis, this selective effect on the metabolism of LpA-I:A-II may provide a potential explanation why patients with classic LCAT deficiency and Fish-eye disease are not at increased risk for premature atherosclerosis despite markedly decreased levels of HDL cholesterol and apoA-I.
|
8282802 |
1994 |
|
Arteriosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
These results suggest that enrichment of apo A-II in high-density lipoprotein particles has atheroprotective effects and apo A-II may become a target for the treatment of atherosclerosis.
|
23241412 |
2013 |
|
Arteriosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
New Zealand White (NZW) rabbits have low plasma total cholesterol concentrations, high cholesteryl ester transfer protein activity, low hepatic lipase (HL) activity, and lack an analogue of human apolipoprotein (apo) A-II, providing a unique system in which to assess the effects of human transgenes on plasma lipoproteins and atherosclerosis susceptibility.
|
10064724 |
1999 |
|
Arteriosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
The distribution of apolipoprotein (apo) J during the development of atherosclerosis in the human aorta was evaluated by immununohistochemical observation, together with the other apolipoprotein A-I, A-II, B, C-III, and E. Although apoJ was never observed in the normal aorta (ie, without any intimal lesions or intimal thickening), it was distributed not only in the intima but also in the media of aortas with diffuse, intimal thickening or atherosclerotic lesions.
|
9555874 |
1998 |
|
Arteriosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Overexpression of human apolipoprotein (apo) A-II in transgenic mice induces high-density lipoprotein (HDL) deficiency, and increased atherosclerosis susceptibility only when fed an atherogenic diet.
|
15994442 |
2005 |
|
Atherosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Overexpression of human apolipoprotein (apo) A-II in transgenic mice induces high-density lipoprotein (HDL) deficiency, and increased atherosclerosis susceptibility only when fed an atherogenic diet.
|
15994442 |
2005 |
|
Atherosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Because LpA-I has been proposed to be more protective than LpA-I:A-II against atherosclerosis, this selective effect on the metabolism of LpA-I:A-II may provide a potential explanation why patients with classic LCAT deficiency and Fish-eye disease are not at increased risk for premature atherosclerosis despite markedly decreased levels of HDL cholesterol and apoA-I.
|
8282802 |
1994 |
|
Atherosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
These results suggest that enrichment of apo A-II in high-density lipoprotein particles has atheroprotective effects and apo A-II may become a target for the treatment of atherosclerosis.
|
23241412 |
2013 |
|
Atherosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
New Zealand White (NZW) rabbits have low plasma total cholesterol concentrations, high cholesteryl ester transfer protein activity, low hepatic lipase (HL) activity, and lack an analogue of human apolipoprotein (apo) A-II, providing a unique system in which to assess the effects of human transgenes on plasma lipoproteins and atherosclerosis susceptibility.
|
10064724 |
1999 |
|
Atherosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Nevertheless, some effects of apo A-II on intermediate HDL metabolism might improve reverse cholesterol transport and might reduce atherosclerosis development while some other effects might be deleterious.
|
12119188 |
2002 |
|
Atherosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
The distribution of apolipoprotein (apo) J during the development of atherosclerosis in the human aorta was evaluated by immununohistochemical observation, together with the other apolipoprotein A-I, A-II, B, C-III, and E. Although apoJ was never observed in the normal aorta (ie, without any intimal lesions or intimal thickening), it was distributed not only in the intima but also in the media of aortas with diffuse, intimal thickening or atherosclerotic lesions.
|
9555874 |
1998 |